嵌合抗原受体 T 细胞疗法治疗慢性淋巴细胞白血病：成功与不足。
CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings.
机构信息
Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Department of Ophthalmology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
出版信息
Curr Oncol. 2022 May 18;29(5):3647-3657. doi: 10.3390/curroncol29050293.
Chimeric antigen receptor T (CAR T) cell therapy achieved remarkable success in B-cell leukemia and lymphoma which led to its incorporation in treatment protocols for these diseases. CAR T cell therapy for chronic lymphocytic leukemia (CLL) patients showed less success compared to other malignant tumors. In this review, we discuss the published results regarding CAR T cell therapy of CLL, possible mechanisms of failures and expected developments.
嵌合抗原受体 T（CAR T）细胞疗法在 B 细胞白血病和淋巴瘤中取得了显著成功，这使其被纳入这些疾病的治疗方案中。与其他恶性肿瘤相比，CAR T 细胞疗法治疗慢性淋巴细胞白血病（CLL）患者的效果较差。在这篇综述中，我们讨论了关于 CLL 的 CAR T 细胞治疗的已发表结果、失败的可能机制以及预期的发展。
Zotero 插件